Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.

Joao GoncalvesM SantosR AcurcioI IriaL GouveiaP Matos BritoA Catarina Cunha-SantosA BarbasJ GalvãoI BarbosaF Aires da SilvaA AlcobiaM CavacoM CardosoJ Delgado AlvesJ J CareyT DörnerJ Eurico FonsecaC PalmelaJ TorresC Lima VieiraD TrabucoG FiorinoAnne S StrikM YavzoriI RosaL CorreiaFernando MagroG D'HaensS Ben-HorinPeter Laszlo LakatosS Danese

Published in: Alimentary pharmacology & therapeutics (2018)

These results strongly support a similar antigenic profile for infliximab originator and CT-P13, and point toward a safe switching between the two drugs in anti-drug antibody negative patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
computed tomography
peritoneal dialysis
prognostic factors
magnetic resonance imaging
ulcerative colitis
dual energy
adverse drug